Tom Henderson, former Moore Capital and Cazenove fund manager, is to launch a trust which will donate 1% of its targeted double-digit returns to charity each year.
The trust has the backing from industry veterans Peter Hames, Jeremy Tigue and Jon Moulton, with its strategic advisory team comprising Jupiter star manager John Chatfeild-Roberts and Moore Capital hedge fund manager Greg Coffey, according to promotional material seen by Wealth Manager.
Henderson, a relation of Henderson equity income manager James Henderson, is seeking to raise £250 million for the Bacit trust, which will target returns of 10-15% per annum through a portfolio of long-only and alternative funds across a range of asset classes.
Big industry hitters have been attracted to the trust's innovative charitable twist, which would see the management team charge no performance or management fees, with the intention of investing 1% of the trust's net asset value (NAV) each year to projects undertaken by the The Institute of Cancer Research (ICR).
Henderson will absorb the costs borne by the management team, which expects the total expense ratio will be around 28 basis points if £250 million is raised successfully.
The closed-ended fund has so far attracted support, with its board of directors including Tigue (pictured), manager of the £2.1 billion Foreign & Colonial trust, Aberdeen Asset Management ex-head of Asia equities Hames, Colin Maltby, former head of pensions at BP, alongside venture capitalist Moulton.
Its strategic advisory is also set to comprise of Jupiter star manager John Chatfeild-Roberts, Moore Capital hedge fund manager Greg Coffey, although a spokesperson said this is subject to confirmation.
Henderson, alongside Jorge Villon, formerly of Polygon Investment Partners, will allocate around 39% towards hedge funds, with 36% in long-biased funds. BlackRock UK Special Situations, Baker Steel Genus Dynamic Gold fund, and Permira V funds are likely to appear in the portfolio.
Underlying fund investments will be made on a gross return basis, which will allow Bacit to not bear the impact of management or performance fees, while the 1% annual donation from the trust will go to the Bacit Foundation with half going straight to the ICR, while investors can determine the split of remaining donation from a range of cancer charities.